Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 16037760)

1.

Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene.

Duvernoy CS, Kulkarni PM, Dowsett SA, Keech CA.

Menopause. 2005 Jul-Aug;12(4):444-52. Epub 2005 Jul 21.

PMID:
16037760
2.

[2010. What novelties are there in vascular risk?].

Alvarez-Sala Walther LA, Suárez Fernández C, Camafort Babkowski M; Grupo de Trabajo de Riesgo Vascular de la SEMI.

Rev Clin Esp. 2011 Sep;211(8):410-22. doi: 10.1016/j.rce.2011.05.019. Epub 2011 Aug 4. Spanish.

PMID:
21816397
3.

Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).

Freeman DJ, Robertson M, Brown EA, Rumley A, Tobias ES, Frölich M, Slagboom PE, Jukema JW, de Craen AJ, Sattar N, Ford I, Gaw A, Greer IA, Lowe GD, Stott DJ.

BMC Geriatr. 2011 Feb 22;11:8. doi: 10.1186/1471-2318-11-8.

4.

Raloxifene temporarily reduces arterial stiffness.

Obayashi S, Terauchi M, Kato K, Akiyoshi M, Kubota T.

J Obstet Gynaecol Res. 2010 Dec;36(6):1229-35. doi: 10.1111/j.1447-0756.2010.01310.x. Epub 2010 Oct 11.

PMID:
21040206
5.

Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis.

Melamed ML, Blackwell T, Neugarten J, Arnsten JH, Ensrud KE, Ishani A, Cummings SR, Silbiger SR.

Kidney Int. 2011 Jan;79(2):241-9. doi: 10.1038/ki.2010.378. Epub 2010 Oct 6.

PMID:
20927038
6.

Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial.

Duvernoy CS, Yeo AA, Wong M, Cox DA, Kim HM.

J Womens Health (Larchmt). 2010 Aug;19(8):1459-65. doi: 10.1089/jwh.2009.1687.

PMID:
20626269
7.

Arterial thrombosis complicates myeloma?

Lacy MQ.

Blood. 2010 Jul 8;116(1):2-3. doi: 10.1182/blood-2010-04-277467.

8.

Effect of Raloxifene on all-cause mortality.

Grady D, Cauley JA, Stock JL, Cox DA, Mitlak BH, Song J, Cummings SR.

Am J Med. 2010 May;123(5):469.e1-7. doi: 10.1016/j.amjmed.2009.12.018. Erratum in: Am J Med. 2010 Oct;123(10):e13.

PMID:
20399327
9.

Serum calcium, phosphorus and cardiovascular events in post-menopausal women.

Slinin Y, Blackwell T, Ishani A, Cummings SR, Ensrud KE; MORE Investigators.

Int J Cardiol. 2011 Jun 16;149(3):335-40. doi: 10.1016/j.ijcard.2010.02.013. Epub 2010 Mar 1.

PMID:
20189664
10.

Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis.

Becattini C, Vedovati MC, Ageno W, Dentali F, Agnelli G.

J Thromb Haemost. 2010 May;8(5):891-7. doi: 10.1111/j.1538-7836.2010.03777.x. Epub 2010 Jan 22. Review.

PMID:
20095999
11.

Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A; ALLHAT Collaborative Research Group.

J Am Coll Cardiol. 2009 Nov 24;54(22):2023-31. doi: 10.1016/j.jacc.2009.08.020.

12.

Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.

Huang WF, Tsai YW, Wen YW, Hsiao FY, Kuo KN, Tsai CR.

Menopause. 2010 Jan-Feb;17(1):57-63. doi: 10.1097/gme.0b013e3181b34749.

PMID:
19680161
13.

Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.

Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G.

Fertil Steril. 2009 Sep;92(3):1045-52. doi: 10.1016/j.fertnstert.2009.02.093. Epub 2009 Jul 26.

PMID:
19635616
14.

Raloxifene and risk for stroke based on the framingham stroke risk score.

Barrett-Connor E, Cox DA, Song J, Mitlak B, Mosca L, Grady D.

Am J Med. 2009 Aug;122(8):754-61. doi: 10.1016/j.amjmed.2009.01.033. Epub 2009 Jun 18.

PMID:
19540454
15.

Blood pressure variables and cardiovascular risk: new findings from ADVANCE.

Kengne AP, Czernichow S, Huxley R, Grobbee D, Woodward M, Neal B, Zoungas S, Cooper M, Glasziou P, Hamet P, Harrap SB, Mancia G, Poulter N, Williams B, Chalmers J; ADVANCE Collaborative Group.

Hypertension. 2009 Aug;54(2):399-404. doi: 10.1161/HYPERTENSIONAHA.109.133041. Epub 2009 May 26.

16.

Endogenous sex hormone levels in men are not associated with risk of venous thromboembolism: the Tromso study.

Svartberg J, Braekkan SK, Laughlin GA, Hansen JB.

Eur J Endocrinol. 2009 May;160(5):833-8. doi: 10.1530/EJE-08-0888. Epub 2009 Feb 10.

17.

Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors.

Collins P, Mosca L, Geiger MJ, Grady D, Kornitzer M, Amewou-Atisso MG, Effron MB, Dowsett SA, Barrett-Connor E, Wenger NK.

Circulation. 2009 Feb 24;119(7):922-30. doi: 10.1161/CIRCULATIONAHA.108.817577. Epub 2009 Feb 9.

18.

Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.

Valiati B, Capp E, Edelweiss MI, de Freitas FM, Wender MC.

Maturitas. 2009 Jan 20;62(1):81-4. doi: 10.1016/j.maturitas.2008.10.013. Epub 2008 Dec 20.

PMID:
19097715
19.

Raloxifene use in clinical practice: efficacy and safety.

Goldstein SR, Duvernoy CS, Calaf J, Adachi JD, Mershon JL, Dowsett SA, Agnusdei D, Stuenkel CA.

Menopause. 2009 Mar-Apr;16(2):413-21. doi: 10.1097/gme.0b013e3181883dae. Review.

PMID:
19092711
20.

Chemoprevention of breast cancer.

Thomsen A, Kolesar JM.

Am J Health Syst Pharm. 2008 Dec 1;65(23):2221-8. doi: 10.2146/ajhp070663. Review.

PMID:
19020189
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk